AR117192A1 - ANTICUERPO BIESPECÍFICO HETERODIMÉRICO SIMILAR EN ESTRUCTURA AL ANTICUERPO NATURAL ANTI-TNFa / ANTI-IL-17A, Y MÉTODO PARA SU PREPARACIÓN - Google Patents

ANTICUERPO BIESPECÍFICO HETERODIMÉRICO SIMILAR EN ESTRUCTURA AL ANTICUERPO NATURAL ANTI-TNFa / ANTI-IL-17A, Y MÉTODO PARA SU PREPARACIÓN

Info

Publication number
AR117192A1
AR117192A1 ARP190103236A ARP190103236A AR117192A1 AR 117192 A1 AR117192 A1 AR 117192A1 AR P190103236 A ARP190103236 A AR P190103236A AR P190103236 A ARP190103236 A AR P190103236A AR 117192 A1 AR117192 A1 AR 117192A1
Authority
AR
Argentina
Prior art keywords
antibody
tnfa
preparation
heterodimeric
natural
Prior art date
Application number
ARP190103236A
Other languages
English (en)
Inventor
Maengsup Kim
Chulwoong Chung
Wenchu Xiao
Nanmeng Song
Yaping Yang
Jiawang Liu
Original Assignee
Beijing Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Hanmi Pharmaceutical Co Ltd filed Critical Beijing Hanmi Pharmaceutical Co Ltd
Publication of AR117192A1 publication Critical patent/AR117192A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente se relaciona con un anticuerpo biespecífico heterodimérico similar en estructura al anticuerpo natural anti-TNFa / anti-IL-17A, y un método para su preparación. Específicamente, la presente provee un anticuerpo biespecífico heterodimérico anti-TNFa / anti-IL-17A muy estable que tiene las características de una IgG natural y que no tiene cadenas pesadas y livianas no correspondientes, y un método para su preparación. El anticuerpo biespecífico tiene la capacidad de unirse de manera simultánea a los dos tipos de moléculas diana, y por lo tanto es más eficaz para tratar enfermedades complejas.
ARP190103236A 2018-11-05 2019-11-05 ANTICUERPO BIESPECÍFICO HETERODIMÉRICO SIMILAR EN ESTRUCTURA AL ANTICUERPO NATURAL ANTI-TNFa / ANTI-IL-17A, Y MÉTODO PARA SU PREPARACIÓN AR117192A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201811307673 2018-11-05

Publications (1)

Publication Number Publication Date
AR117192A1 true AR117192A1 (es) 2021-07-21

Family

ID=70611661

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190103236A AR117192A1 (es) 2018-11-05 2019-11-05 ANTICUERPO BIESPECÍFICO HETERODIMÉRICO SIMILAR EN ESTRUCTURA AL ANTICUERPO NATURAL ANTI-TNFa / ANTI-IL-17A, Y MÉTODO PARA SU PREPARACIÓN

Country Status (11)

Country Link
US (1) US20220010006A1 (es)
EP (1) EP3878870A4 (es)
JP (1) JP2022506411A (es)
KR (1) KR20210088611A (es)
CN (1) CN112930358B (es)
AR (1) AR117192A1 (es)
AU (1) AU2019374190B2 (es)
BR (1) BR112021008701A2 (es)
CA (1) CA3118612A1 (es)
TW (1) TWI825214B (es)
WO (1) WO2020093990A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY194994A (en) * 2016-09-29 2022-12-30 Beijing Hanmi Pharmaceutical Co Ltd Heterodimeric immunoglobulin constructs and preparation methods thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI9707379B8 (pt) * 1996-02-09 2015-07-07 Abbvie Biotechnology Ltd Composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado.
NZ574804A (en) 2006-08-11 2012-02-24 Schering Corp Antibodies to il-17a
PL2635607T3 (pl) * 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
TWI687439B (zh) * 2011-06-30 2020-03-11 中外製藥股份有限公司 異源二聚化多胜肽
US9127055B2 (en) * 2013-02-08 2015-09-08 Astellas Pharma Inc. Method of treating pain with anti-human NGF antibody
TW201444867A (zh) * 2013-03-08 2014-12-01 Lilly Co Eli 抗ｔｎｆ－抗ｉｌ－１７雙特異性抗體
WO2015014979A1 (en) * 2013-08-01 2015-02-05 F. Hoffmann-La Roche Ag Tnfa-il-17 bispecific antibodies
CN103897300A (zh) * 2014-04-11 2014-07-02 东莞市烨青电业有限公司 一种透明pvc热稳定剂
MA46681A (fr) * 2016-01-28 2019-09-11 Janssen Biotech Inc Anticorps bispécifiques anti-tnf-alpha/il-17a antibodies et anticorps anti-tnf-alpha et leurs procédés d'utilisation
US11072651B2 (en) * 2016-09-14 2021-07-27 Beijing Hanmi Pharm. Co., Ltd. Antibody specifically binding to IL-17A, encoding nucleic acid, and method of using the antibody
MY194994A (en) * 2016-09-29 2022-12-30 Beijing Hanmi Pharmaceutical Co Ltd Heterodimeric immunoglobulin constructs and preparation methods thereof
US11319378B2 (en) * 2016-11-18 2022-05-03 Beijing Hanmi Pharmaceutical Co., Ltd. Anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same
CA3058009A1 (en) * 2017-04-01 2018-10-04 Beijing Hanmi Pharm. Co., Ltd. Anti-pd-l1/anti-pd-1 natural antibody structure-like heterodimeric bispecific antibody and preparation thereof

Also Published As

Publication number Publication date
TW202017942A (zh) 2020-05-16
CN112930358B (zh) 2023-02-21
EP3878870A1 (en) 2021-09-15
TWI825214B (zh) 2023-12-11
JP2022506411A (ja) 2022-01-17
US20220010006A1 (en) 2022-01-13
CA3118612A1 (en) 2020-05-14
AU2019374190B2 (en) 2024-02-22
KR20210088611A (ko) 2021-07-14
AU2019374190A1 (en) 2021-05-27
WO2020093990A1 (zh) 2020-05-14
BR112021008701A2 (pt) 2021-08-17
CN112930358A (zh) 2021-06-08
EP3878870A4 (en) 2022-08-03

Similar Documents

Publication Publication Date Title
EA201990285A1 (ru) Гетеродимерные иммуноглобулиновые конструкции и способы их получения
CY1120849T1 (el) Αντισωμα που συνδεεται σε ανθρωπινο cd3
DOP2019000124A (es) Anticuerpo biespecífico heterodimérico estructural de anticuerpo natural anti-pd-1/anti-her2 y método para preparar el mismo
EA201791961A1 (ru) Антитела, специфичные к cd47 и pd-l1
PE20210132A1 (es) Anticuerpos anti-cd3 y usos de estos
PE20181167A1 (es) Proteinas de union triespecificas y/o trivalentes para la prevencion o el tratamiento de la infeccion por vih
AR111418A1 (es) Dominios de unión a antígeno humanizados y métodos de uso
ECSP18043564A (es) Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
EA201491569A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С СИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
EA201791527A1 (ru) Биспецифические антитела против плазменного калликреина и фактора xii
PE20210180A1 (es) Anticuerpos anti-cd33, anticuerpos biespecificos anti-cd33/anti-cd3 y usos de estos
AR106184A1 (es) Proteínas de unión a pd-1 y sus métodos de uso
UY37127A (es) Moléculas de unión a ror1, y métodos de uso de las mismas
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
AR098979A1 (es) Los fragmentos fab de la inmunoglobulina en tándem y sus usos
CL2021001628A1 (es) Anticuerpo humanizado anti-pd-1 humana
AR087601A1 (es) Anticuerpos sin fc que comprenden dos fragmentos fab y metodos de utilizacion
PE20151289A1 (es) Anticuerpos que se unen al tl1a y sus usos
AR084315A1 (es) Anticuerpos anti-notch1
BR112021026890A2 (pt) Composições de anticorpo para interromper biofilmes
AR101202A1 (es) Anticuerpo anti-tie2 humana
AR086984A1 (es) Anticuerpo anti-cxcr4 con funciones efectoras y su uso en el tratamiento del cancer
EA202091888A1 (ru) Вариабельные домены антител, нацеленные на рецептор nkg2d
UY38672A (es) Anticuerpo monoclonal que se une específicamente a gitr
PE20201171A1 (es) Anticuerpos de cadena pesada que se unen a cd22